IP Library › Granted Patent US 7,560,463
Granted Patent B2
US 7,560,463 · App. 12/052,994 · Granted Jul 14, 2009

Diaryl ethers as opioid receptor antagonists

Assignee: Eli Lilly and Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,560,463
App. No.
12/052,994
Granted
Jul 14, 2009
Kind
B2
Abstract

Compound 5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof, useful for the treatment of irritable bowel syndrome.

Claims (2)

1. A method of treating irritable bowel syndrome in a patient in need thereof, which comprises administering a therapeutically effective amount of 5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide, or a pharmaceutically acceptable salt thereof, to said patient.

2. The method of claim 1 wherein said patient is human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2008
From: MITCH, CHARLES HOWARD; STATNICK, MICHAEL ANGELO
To: ELI LILLY AND COMPANY
Reel/Frame 021190/0715 →
Continuity (3)
Continuation 1052696000
Provisional Application 6041215800 · Sep 19, 2002
Related Publication 20080255152A1 · Oct 16, 2008